US6100071A
(en)
*
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
US7070959B1
(en)
*
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
US20090155266A1
(en)
*
|
2004-01-16 |
2009-06-18 |
Yale University |
Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
|
EP1732947B1
(en)
*
|
2004-03-05 |
2011-04-27 |
Vegenics Pty Ltd |
Growth factor binding constructs materials and methods
|
CN101102786A
(zh)
*
|
2004-06-10 |
2008-01-09 |
瑞泽恩制药公司 |
施用并利用vegf抑制剂治疗人类癌症的方法
|
BRPI0515264B1
(pt)
|
2004-09-13 |
2018-12-18 |
Genzyme Corp |
proteína de fusão de acordo com fórmula x-y-z, composição, molécula de ácido nucleico, seus usos e método de multimerização de um polipeptídeo x
|
US20060134121A1
(en)
*
|
2004-10-29 |
2006-06-22 |
Gavin Thurston |
DII4 antagonists, assays, and therapeutic methods thereof
|
US8048418B2
(en)
|
2004-10-29 |
2011-11-01 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
|
FR2878749B1
(fr)
*
|
2004-12-03 |
2007-12-21 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
|
JP2008537538A
(ja)
*
|
2005-02-11 |
2008-09-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Vegf拮抗剤及び降圧剤の治療的組み合わせ
|
PT2586459T
(pt)
*
|
2005-03-25 |
2017-07-25 |
Regeneron Pharma |
Formulações antagonistas de fcev
|
WO2007022101A2
(en)
*
|
2005-08-12 |
2007-02-22 |
Regeneron Pharmaceuticals, Inc. |
Treatment of diseases by subcutaneous administration of a vegf antagonist
|
WO2007041614A2
(en)
*
|
2005-10-03 |
2007-04-12 |
Bolder Biotechnology, Inc. |
Long acting vegf inhibitors and methods of use
|
ES2400666T5
(es)
*
|
2005-12-16 |
2016-03-10 |
Regeneron Pharmaceuticals, Inc. |
Uso terapéutico de un antagonista de DII4 y un inhibidor de VEGF para inhibir el crecimiento tumoral
|
FR2895258B1
(fr)
*
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
Combinaison comprenant de la combretastatine et des agents anticancereux
|
CN100502945C
(zh)
*
|
2006-03-31 |
2009-06-24 |
成都康弘生物科技有限公司 |
Vegf受体融合蛋白在治疗眼睛疾病中的应用
|
US8216575B2
(en)
*
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
EP3753548A1
(en)
|
2006-06-16 |
2020-12-23 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
WO2008005290A2
(en)
|
2006-06-29 |
2008-01-10 |
The Trustees Of Columbia University In The City Of New York |
Methods for testing anti-thrombotic agents
|
US8920808B2
(en)
|
2006-10-31 |
2014-12-30 |
East Carolina University |
Cytokine-based fusion proteins for treatment of multiple sclerosis
|
PL2185589T3
(pl)
|
2007-06-01 |
2016-09-30 |
|
Środki wiążące receptor regionu stałego Fc immunoglobuliny
|
TWI436775B
(zh)
*
|
2007-08-24 |
2014-05-11 |
Oncotherapy Science Inc |
以抗原胜肽合併化療藥劑治療胰臟癌
|
EP2282769A4
(en)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
EP2297209A4
(en)
|
2008-06-03 |
2012-08-01 |
Abbott Lab |
IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
|
RU2550258C2
(ru)
*
|
2008-11-03 |
2015-05-10 |
Молекьюлар Партнерс Аг |
Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
|
WO2010054221A2
(en)
*
|
2008-11-06 |
2010-05-14 |
The Johns Hopkins University |
Treatment of chronic inflammatory respiratory disorders
|
EP3348275A3
(en)
|
2009-03-31 |
2018-10-24 |
East Carolina University |
Cytokines and neuroantigens for treatment of immune disorders
|
WO2010127029A1
(en)
*
|
2009-05-01 |
2010-11-04 |
Ophthotech Corporation |
Methods for treating or preventing ophthalmological diseases
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
CA2800173C
(en)
|
2010-05-21 |
2019-05-14 |
Ulrik Nielsen |
Bi-specific fusion proteins
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
PL2598533T3
(pl)
|
2010-07-28 |
2019-07-31 |
Gliknik Inc. |
Białka fuzyjne naturalnych fragmentów białka ludzkiego do tworzenia uporządkowanych multimeryzowanych kompozycji Fc immunoglobulin
|
JP2013537415A
(ja)
|
2010-08-03 |
2013-10-03 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
LT2601214T
(lt)
|
2010-08-06 |
2018-02-26 |
Genzyme Corporation |
Vegf antagonistų kompozicijos ir jų panaudojimas
|
US9518132B2
(en)
*
|
2010-11-09 |
2016-12-13 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
CA2824422A1
(en)
|
2011-01-13 |
2012-07-19 |
Regeneron Pharmaceuticals, Inc. |
Use of a vegf antagonist to treat angiogenic eye disorders
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
AU2012299195B9
(en)
|
2011-08-19 |
2018-05-10 |
Regeneron Pharmaceuticals, Inc |
Anti-Tie2 antibodies uses thereof
|
DK2744508T3
(da)
|
2011-08-19 |
2018-02-19 |
Harvard College |
Vegf-bindende protein til blokering af angiogenese
|
CA2849508C
(en)
|
2011-09-30 |
2020-12-22 |
Regeneron Pharmaceuticals, Inc. |
Anti-erbb3 antibodies and uses thereof
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
AU2012340107B2
(en)
|
2011-11-18 |
2017-06-15 |
Regeneron Pharmaceuticals, Inc. |
Polymer protein microparticles
|
BR112014013205A2
(pt)
*
|
2011-12-01 |
2020-10-27 |
Protevobio, Inc. |
proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
|
TWI613215B
(zh)
|
2012-02-22 |
2018-02-01 |
再生元醫藥公司 |
抗-大-內皮素-1(big-et-1)抗體及其用途
|
US20130243775A1
(en)
|
2012-03-14 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules and uses thereof
|
TWI698240B
(zh)
|
2012-05-15 |
2020-07-11 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
TWI641619B
(zh)
|
2012-06-25 |
2018-11-21 |
美商再生元醫藥公司 |
抗-egfr抗體及其用途
|
KR20150058236A
(ko)
|
2012-08-20 |
2015-05-28 |
글리크닉 인코포레이티드 |
항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
|
RU2542385C2
(ru)
*
|
2012-08-31 |
2015-02-20 |
Общество с ограниченной ответственностью "НекстГен" |
Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
WO2014078306A1
(en)
|
2012-11-13 |
2014-05-22 |
Regeneron Pharmaceuticals, Inc. |
Anti-prokineticin receptor (prokr) antibodies and uses thereof
|
JO3405B1
(ar)
|
2013-01-09 |
2019-10-20 |
Regeneron Pharma |
الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
|
NZ710658A
(en)
*
|
2013-02-18 |
2019-12-20 |
Vegenics Pty Ltd |
Ligand binding molecules and uses thereof
|
ES2898620T3
(es)
|
2013-03-14 |
2022-03-08 |
Regeneron Pharma |
Anticuerpos humanos contra GREM 1
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
KR102049990B1
(ko)
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
SG11201510315TA
(en)
|
2013-07-12 |
2016-01-28 |
Ophthotech Corp |
Methods for treating or preventing ophthalmological conditions
|
KR102060187B1
(ko)
|
2013-07-19 |
2019-12-27 |
삼성전자주식회사 |
Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도
|
WO2015058369A1
(en)
*
|
2013-10-23 |
2015-04-30 |
Sanofi (China) Investment Co., Ltd. |
Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
CN106459199B
(zh)
|
2014-03-11 |
2021-01-01 |
瑞泽恩制药公司 |
抗-egfrviii抗体及其用途
|
CA2942776C
(en)
|
2014-03-17 |
2023-01-24 |
Adverum Biotechnologies, Inc. |
Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
LT3170005T
(lt)
|
2014-07-18 |
2019-07-10 |
Sanofi |
Paciento, įtariamo, kad serga vėžiu, gydymo afliberceptu rezultato prognozavimo būdas
|
WO2016025645A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
JP6800141B2
(ja)
|
2014-08-12 |
2020-12-16 |
マサチューセッツ インスティテュート オブ テクノロジー |
Il−2およびインテグリン結合性fc融合タンパク質による相乗的な腫瘍処置
|
AR102198A1
(es)
|
2014-10-09 |
2017-02-08 |
Regeneron Pharma |
Proceso para reducir partículas subvisibles en una formulación farmacéutica
|
EP3699198A1
(en)
|
2014-11-17 |
2020-08-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for tumor treatment using cd3xcd20 bispecific antibody
|
US20160144025A1
(en)
*
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
EA201791939A1
(ru)
|
2015-03-02 |
2018-01-31 |
Адверум Байотекнолоджиз, Инк. |
Композиции и способы интравитреальной доставки полинуклеотидов в колбочки сетчатки
|
TW202336236A
(zh)
|
2015-03-27 |
2023-09-16 |
美商再生元醫藥公司 |
偵測生物污染物之組成物及方法
|
CN107995912A
(zh)
|
2015-03-27 |
2018-05-04 |
里珍纳龙药品有限公司 |
美登素类衍生物、其偶联物和使用方法
|
CN107847395B
(zh)
*
|
2015-04-23 |
2021-10-15 |
新健康科学股份有限公司 |
厌氧血液储存容器
|
PL3294775T3
(pl)
|
2015-05-12 |
2021-12-13 |
Regeneron Pharmaceuticals, Inc. |
Oznaczanie czystości białka multimerycznego
|
RU2612497C2
(ru)
|
2015-05-26 |
2017-03-09 |
Общество с ограниченной ответственностью "НекстГен" |
Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
TW202330904A
(zh)
|
2015-08-04 |
2023-08-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
EP3353212B1
(en)
|
2015-09-23 |
2021-11-03 |
Regeneron Pharmaceuticals, Inc. |
Optimized anti-cd3 bispecific antibodies and uses thereof
|
CA2998390A1
(en)
|
2015-09-28 |
2017-04-06 |
East Carolina University |
Aluminum based adjuvants for tolerogenic vaccination
|
US10040840B2
(en)
|
2015-10-02 |
2018-08-07 |
Silver Creek Pharmaceuticals, Inc. |
Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗lag3抗體及其用途
|
WO2017070866A1
(zh)
*
|
2015-10-28 |
2017-05-04 |
黄志清 |
一种抗血管内皮生长因子的氧化石墨烯与其用途
|
EP3377101A4
(en)
*
|
2015-11-19 |
2019-08-07 |
Zhuhai Tairuishang Biopharm Ltd. |
VEGF BINDING METHODS AND COMPOSITIONS
|
CN108474039B
(zh)
|
2015-12-03 |
2022-06-07 |
雷杰纳荣制药公司 |
抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途
|
CN108602890A
(zh)
|
2015-12-11 |
2018-09-28 |
瑞泽恩制药公司 |
用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
|
PL3389636T3
(pl)
|
2015-12-16 |
2022-11-28 |
Regeneron Pharmaceuticals, Inc. |
Kompozycje i metody wytwarzania mikrocząstek białkowych
|
RS64588B1
(sr)
|
2015-12-22 |
2023-10-31 |
Regeneron Pharma |
Kombinacija anti-pd-1 antitela i bispecifičnih anti-cd20/anti-cd3 antitela za lečenje kancera
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
SG11201806322QA
(en)
|
2016-01-25 |
2018-08-30 |
Regeneron Pharma |
Maytansinoid derivatives, conjugates thereof, and methods of use
|
EP3448891A1
(en)
|
2016-04-28 |
2019-03-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
ES2908467T3
(es)
|
2016-04-29 |
2022-04-29 |
Adverum Biotechnologies Inc |
Evasión de anticuerpos neutralizantes por un virus adenoasociado recombinante
|
TWI822521B
(zh)
|
2016-05-13 |
2023-11-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
US11034775B2
(en)
|
2016-06-07 |
2021-06-15 |
Gliknik Inc. |
Cysteine-optimized stradomers
|
SG11201810525XA
(en)
|
2016-06-10 |
2018-12-28 |
Regeneron Pharma |
Anti-gitr antibodies and uses thereof
|
EP3491559A1
(en)
|
2016-07-29 |
2019-06-05 |
Regeneron Pharmaceuticals, Inc. |
Assembly line with integrated electronic visual inspection
|
KR102369014B1
(ko)
|
2016-08-16 |
2022-03-02 |
리제너론 파아마슈티컬스, 인크. |
혼합물로부터 개별 항체들을 정량하는 방법
|
EP3500856B1
(en)
|
2016-08-18 |
2020-10-07 |
Regeneron Pharmaceuticals, Inc. |
Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
WO2018067331A1
(en)
|
2016-09-23 |
2018-04-12 |
Regeneron Pharmaceuticals, Inc. |
Bi specific anti-muc16-cd3 antibodies and nti-muc16 drug conjugates
|
CA3037732A1
(en)
|
2016-09-23 |
2018-03-29 |
Regeneron Pharmaceuticals, Inc. |
Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
|
IL310367A
(en)
|
2016-10-07 |
2024-03-01 |
Regeneron Pharma |
A stable protein at room temperature that has been lyophilized
|
CA3040179A1
(en)
|
2016-10-19 |
2018-04-26 |
Adverum Biotechnologies, Inc. |
Modified aav capsids and uses thereof
|
KR20230119729A
(ko)
|
2016-10-25 |
2023-08-16 |
리제너론 파아마슈티컬스, 인크. |
크로마토그래피 데이터 분석을 위한 방법 및 시스템
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
|
US11135266B2
(en)
|
2016-11-21 |
2021-10-05 |
Just-Evotec Biologics, Inc. |
Aflibercept formulations and uses thereof
|
EP3548514A1
(en)
|
2016-11-29 |
2019-10-09 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating prlr positive breast cancer
|
AU2017371179B2
(en)
|
2016-12-09 |
2022-07-14 |
Gliknik Inc. |
Manufacturing optimization of GL-2045, a multimerizing stradomer
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
WO2018132516A1
(en)
|
2017-01-10 |
2018-07-19 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
|
IL268667B1
(en)
|
2017-02-10 |
2024-08-01 |
Regeneron Pharma |
Radiolabeled antibodies against LAG3 for immuno-PET imaging
|
CA3054289A1
(en)
|
2017-02-21 |
2018-08-30 |
Regeneron Pharmaceuticals, Inc. |
Anti-pd-1 antibodies for treatment of lung cancer
|
KR102616820B1
(ko)
|
2017-03-17 |
2023-12-21 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
향상된 유전자 발현을 위한 조성물 및 방법
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
CA3062418A1
(en)
|
2017-05-06 |
2018-11-15 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with aplnr antagonists and vegf inhibitors
|
CN110914295B
(zh)
|
2017-06-28 |
2024-08-09 |
里珍纳龙药品有限公司 |
抗人乳头瘤病毒(hpv)抗原结合蛋白及其使用方法
|
CN114075269A
(zh)
|
2017-07-06 |
2022-02-22 |
菲仕兰坎皮纳荷兰私人有限公司 |
用于制备糖蛋白的细胞培养工艺
|
SG11202000073XA
(en)
|
2017-07-24 |
2020-02-27 |
Regeneron Pharma |
Anti-cd8 antibodies and uses thereof
|
TWI799432B
(zh)
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
CN111132695A
(zh)
*
|
2017-08-18 |
2020-05-08 |
里珍纳龙药品有限公司 |
分析样品基质中蛋白变异体的成像毛细管等电聚焦
|
BR112020005335A2
(pt)
|
2017-09-19 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
métodos para reduzir a formação de partículas e composições formadas pelos mesmos
|
CA3185107A1
(en)
|
2017-10-12 |
2019-04-18 |
Immunowake Inc. |
Vegfr-antibody light chain fusion protein
|
MX2020003945A
(es)
*
|
2017-10-18 |
2020-11-09 |
Regenxbio Inc |
Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .
|
SG11202004268PA
(en)
|
2017-11-30 |
2020-06-29 |
Regeneron Pharma |
Use of a vegf antagonist to treat angiogenic eye disorders
|
EA039731B1
(ru)
|
2017-12-13 |
2022-03-04 |
Ридженерон Фармасьютикалз, Инк. |
Устройства и системы для управления опорой слоя сорбента хроматографической колонки и связанные с ними способы
|
MX2020006639A
(es)
|
2017-12-22 |
2020-09-14 |
Regeneron Pharma |
Sistema y metodo para caracterizar las impurezas de un producto farmaceutico.
|
EA202091786A1
(ru)
|
2018-01-26 |
2020-10-20 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
|
AU2019215363A1
(en)
|
2018-01-31 |
2020-07-23 |
Regeneron Pharmaceuticals, Inc. |
System and method for characterizing size and charge variant drug product impurities
|
TWI825066B
(zh)
|
2018-02-01 |
2023-12-11 |
美商再生元醫藥公司 |
治療性單株抗體之品質屬性的定量及模型化
|
TW202311746A
(zh)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
JP2021514609A
(ja)
|
2018-02-28 |
2021-06-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ウイルス混入物質を同定するためのシステムおよび方法
|
US12071476B2
(en)
|
2018-03-02 |
2024-08-27 |
Kodiak Sciences Inc. |
IL-6 antibodies and fusion constructs and conjugates thereof
|
EP4317959A3
(en)
|
2018-03-19 |
2024-03-27 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
WO2019197676A1
(en)
|
2018-04-13 |
2019-10-17 |
Ludwig Institute For Cancer Research Ltd |
Heterodimeric inactivatable chimeric antigen receptors
|
US12037411B2
(en)
|
2018-04-30 |
2024-07-16 |
Regeneron Pharmaceuticals, Inc. |
Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof
|
TW202348297A
(zh)
|
2018-05-02 |
2023-12-16 |
美商里珍納龍藥品有限公司 |
用於評估生化過濾器的適合性的方法
|
CA3099551A1
(en)
|
2018-05-10 |
2019-11-14 |
Regeneron Pharmaceuticals, Inc. |
High concentration vegf receptor fusion protein containing formulations
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
TW202005985A
(zh)
|
2018-06-21 |
2020-02-01 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法
|
US11884698B2
(en)
|
2018-07-02 |
2024-01-30 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for preparing a polypeptide from a mixture
|
CN112639471B
(zh)
|
2018-08-13 |
2024-04-09 |
瑞泽恩制药公司 |
在模拟体内条件下的治疗性蛋白质选择
|
WO2020047067A1
(en)
|
2018-08-30 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
WO2020086647A1
(en)
|
2018-10-23 |
2020-04-30 |
Regeneron Pharmaceuticals, Inc. |
Ny-eso-1 t cell receptors and methods of use thereof
|
WO2020097155A1
(en)
|
2018-11-06 |
2020-05-14 |
Alsatech, Inc. |
Cell-based gene therapy for neurodegenerative diseases
|
WO2020150491A1
(en)
|
2019-01-16 |
2020-07-23 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing disulfide bonds
|
WO2020154525A1
(en)
|
2019-01-25 |
2020-07-30 |
Regeneron Pharmaceuticals, Inc. |
Quantitation and identification of dimers in co-formulations
|
CN118671361A
(zh)
|
2019-01-25 |
2024-09-20 |
瑞泽恩制药公司 |
蛋白a色谱-电喷雾电离质谱仪
|
US20240254208A2
(en)
|
2019-02-12 |
2024-08-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for using bispecific antibodies to bind complement and a target antigen
|
WO2020172475A1
(en)
|
2019-02-21 |
2020-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
|
MA55204A
(fr)
|
2019-03-06 |
2022-01-12 |
Regeneron Pharma |
Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
|
AU2020257220A1
(en)
|
2019-04-17 |
2021-11-11 |
Regeneron Pharmaceuticals, Inc. |
Identification of host cell proteins
|
US10961500B1
(en)
|
2019-04-23 |
2021-03-30 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium for eukaryotic cells
|
TW202106699A
(zh)
|
2019-04-26 |
2021-02-16 |
美商愛德維仁生物科技公司 |
用於玻璃體內遞送之變異體aav蛋白殼
|
EP3969908A1
(en)
|
2019-05-13 |
2022-03-23 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
MA55965A
(fr)
|
2019-05-13 |
2022-03-23 |
Regeneron Pharma |
Combinaison d'inhibiteurs pd-1 et d'inhibiteurs lag-3 pour une efficacité améliorée dans le traitement du cancer
|
EP3986933A1
(en)
|
2019-06-21 |
2022-04-27 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
|
JP2022537269A
(ja)
|
2019-06-21 |
2022-08-25 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用
|
CN110343666B
(zh)
*
|
2019-07-10 |
2023-05-30 |
通化东宝药业股份有限公司 |
一种cho细胞培养的补料培养基及其制备方法和应用
|
JP2022547274A
(ja)
|
2019-09-16 |
2022-11-11 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
免疫pet撮像のための放射標識されたmet結合タンパク質
|
US11814428B2
(en)
|
2019-09-19 |
2023-11-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-PTCRA antibody-drug conjugates and uses thereof
|
KR20220066393A
(ko)
|
2019-09-24 |
2022-05-24 |
리제너론 파아마슈티컬스, 인크. |
크로마토그래피의 사용 및 재생을 위한 시스템 및 방법
|
US11912784B2
(en)
|
2019-10-10 |
2024-02-27 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
JP2023502501A
(ja)
|
2019-11-25 |
2023-01-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
眼内血管新生のための長時間作用型vegf阻害剤
|
MX2022006236A
(es)
|
2019-11-25 |
2022-06-22 |
Regeneron Pharma |
Formulaciones de liberacion sostenida con emulsiones no acuosas.
|
EP4069264A1
(en)
*
|
2019-12-06 |
2022-10-12 |
Regeneron Pharmaceuticals, Inc. |
Vegf mini-traps and methods of use thereof
|
IL302538A
(en)
|
2019-12-06 |
2023-07-01 |
Regeneron Pharma |
Anti-VEGF protein preparations and methods for their production
|
WO2021123908A1
(en)
|
2019-12-20 |
2021-06-24 |
Ludwig Institute For Cancer Research Ltd |
Car-t cell therapy targeting ngcgm3
|
EP4085253B1
(en)
|
2020-01-21 |
2024-03-13 |
Regeneron Pharmaceuticals, Inc. |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
KR20220131956A
(ko)
|
2020-01-24 |
2022-09-29 |
리제너론 파아마슈티컬스, 인크. |
흑색종에서 우선적으로 발현되는 항원(prame) t 세포 수용체 및 이의 사용 방법
|
MX2022010601A
(es)
|
2020-02-27 |
2022-09-09 |
Regeneron Pharma |
Analisis de proteinas de celula hospedera segun su actividad.
|
US11958910B2
(en)
|
2020-02-28 |
2024-04-16 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen binding molecules that bind HER2, and methods of use thereof
|
CA3168173A1
(en)
|
2020-03-06 |
2021-09-10 |
Robert Babb |
Anti-gitr antibodies and uses thereof
|
US12007396B2
(en)
|
2020-03-30 |
2024-06-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing low-abundance host cell proteins
|
MX2022013812A
(es)
*
|
2020-05-08 |
2022-12-15 |
Regeneron Pharma |
Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
|
WO2021259200A1
(zh)
|
2020-06-22 |
2021-12-30 |
信达生物制药(苏州)有限公司 |
抗ang-2抗体及其用途
|
KR20240038138A
(ko)
|
2020-07-13 |
2024-03-22 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
|
CN115776890A
(zh)
|
2020-07-16 |
2023-03-10 |
拉夸里亚创药株式会社 |
作为眼病治疗剂的trpv4抑制剂
|
AU2021308712A1
(en)
|
2020-07-16 |
2023-02-02 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
MX2023002417A
(es)
|
2020-08-31 |
2023-03-22 |
Regeneron Pharma |
Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina.
|
JP2023544164A
(ja)
|
2020-10-02 |
2023-10-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
サイトカイン放出症候群の低減を伴うがんを治療するための抗体の組合せ
|
KR20230095070A
(ko)
|
2020-10-22 |
2023-06-28 |
리제너론 파마슈티칼스 인코포레이티드 |
항-fgfr2 항체 및 이의 사용 방법
|
AU2021377185A1
(en)
|
2020-11-10 |
2023-06-08 |
Regeneron Pharmaceuticals, Inc. |
Selenium antibody conjugates
|
AU2021385363A1
(en)
|
2020-11-25 |
2023-06-08 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
CA3205135A1
(en)
|
2020-12-17 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
US12031151B2
(en)
|
2021-01-20 |
2024-07-09 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving protein titer in cell culture
|
WO2022159875A1
(en)
|
2021-01-25 |
2022-07-28 |
Regeneron Pharmaceuticals, Inc. |
Anti-pdgf-b antibodies and mehods of use for treating pulmonary arterial hypertension (pah)
|
AU2022217058A1
(en)
|
2021-02-04 |
2023-09-21 |
Genuv Inc. |
Anti-pd-1 antibody and use thereof
|
CA3170208A1
(en)
|
2021-02-11 |
2022-08-18 |
Elizabeth Miller |
Methods of treating cancer by administering a neoadjuvant pd-1 inhibitor
|
IL304998A
(en)
|
2021-02-23 |
2023-10-01 |
Regeneron Pharma |
Methods for the treatment of lung cancer through the administration of a PD-1 inhibitor
|
AR125585A1
(es)
|
2021-03-03 |
2023-08-02 |
Regeneron Pharma |
Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
|
AU2022242000A1
(en)
|
2021-03-23 |
2023-09-14 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
|
WO2022204728A1
(en)
|
2021-03-26 |
2022-09-29 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing mixing protocols
|
EP4349852A1
(en)
|
2021-05-28 |
2024-04-10 |
Shanghai Regenelead Therapies Co., Ltd. |
Recombinant adeno-associated virus having variant capsid, and application thereof
|
WO2022256383A1
(en)
|
2021-06-01 |
2022-12-08 |
Regeneron Pharmaceuticals, Inc. |
Micropchip capillary electrophoresis assays and reagents
|
EP4359440A1
(en)
|
2021-06-22 |
2024-05-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-egfrviii antibody drug conjugates and uses thereof
|
CN117716237A
(zh)
|
2021-07-13 |
2024-03-15 |
瑞泽恩制药公司 |
用于确定生物制剂的产物相关变体的基于质谱法的策略
|
US20230018713A1
(en)
|
2021-07-13 |
2023-01-19 |
Regeneron Pharmaceuticals, Inc. |
Characterization of proteins by anion-exchange chromatography mass spectrometry (aex-ms)
|
TW202326138A
(zh)
|
2021-09-08 |
2023-07-01 |
美商再生元醫藥公司 |
用於定量抗體及其他含Fc蛋白之高通量及基於質譜之方法
|
IL310875A
(en)
|
2021-09-14 |
2024-04-01 |
Regeneron Pharma |
NMASS spectrometry-based strategy for characterizing high molecular weight species of a biological product
|
US20230110651A1
(en)
|
2021-09-28 |
2023-04-13 |
Regeneron Pharmaceuticals, Inc. |
Assays to quantitate drug and target concentrations
|
IL311248A
(en)
|
2021-10-07 |
2024-05-01 |
Regeneron Pharma |
PH meter calibration and repair
|
WO2023059800A2
(en)
|
2021-10-07 |
2023-04-13 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods of ph modeling and control
|
CA3236367A1
(en)
|
2021-10-26 |
2023-05-04 |
Michelle Lafond |
Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
|
CA3236059A1
(en)
|
2021-11-01 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Methods to prevent disulfide scrambling for ms-based proteomics
|
WO2023081925A1
(en)
|
2021-11-08 |
2023-05-11 |
Immatics Biotechnologies Gmbh |
Adoptive cell therapy combination treatment and compositions thereof
|
AU2022398486A1
(en)
|
2021-11-24 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies
|
AU2022402985A1
(en)
|
2021-12-01 |
2024-07-11 |
Kadmon Corporation, Llc |
B7-h4 antibodies and anti-b7-h4 antibody/il-15 fusion proteins
|
AU2023207960A1
(en)
|
2022-01-12 |
2024-07-11 |
Regeneron Pharmaceuticals, Inc. |
Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
|
WO2023177836A1
(en)
|
2022-03-18 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for analyzing polypeptide variants
|
WO2023196903A1
(en)
|
2022-04-06 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
WO2024097642A1
(en)
|
2022-10-31 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine
|
WO2024118785A2
(en)
|
2022-11-30 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Tlr7 agonists and antibody-drug-conjugates thereof
|
US20240198253A1
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
US20240262923A1
(en)
|
2022-12-21 |
2024-08-08 |
Genzyme Corporation |
Anti-pd-1×4-1bb binding proteins
|
US20240269308A1
(en)
|
2022-12-21 |
2024-08-15 |
Regeneron Pharmaceuticals, Inc. |
Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
|
US20240248097A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
WO2024158880A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
US20240279350A1
(en)
|
2023-02-16 |
2024-08-22 |
Sanofi |
CD40-Binding Proteins
|
US20240299601A1
(en)
|
2023-02-17 |
2024-09-12 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
US20240280551A1
(en)
|
2023-02-22 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
WO2024192033A1
(en)
|
2023-03-13 |
2024-09-19 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
|
WO2024211478A1
(en)
|
2023-04-07 |
2024-10-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a lymphotoxin beta receptor agonist
|